Clinical Trial 20760

• Overview

  Study Title:

  Open-Label, Multicenter, Phase 1b /2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous Anti-claudin18.2 Chimeric Antigen Receptor T-cell Therapy in Subjects with Advanced Gastric, Pancreatic, or Other Specified Digestive System Cancers

  Summary:

  This is an open label, multi-center, Phase 1b clinical trial to evaluate the safety and efficacy of autologous claudin18.2 chimeric antigen receptor T-cell therapy in patients with advanced gastric or pancreatic adenocarcinoma.

  Objective:

  Cohort A Primary -Evaluate the safety and tolerability of CAR-CLDN18.2 T-cell therapy (CT041) in patients with advanced STAD or PAAD -Identify the MTD and a RP2D of CT041 therapy in patients with STAD or PAAD Secondary: -Evaluate clinical efficacy outcomes with CAR-CLDN18.2 T-cell therapy (CT041) in patients with advanced STAD or PAAD Exploratory: -Evaluate PK and biodistribution of CAR-CLDN18.2 T-cell therapy (CT041) in patients with STAD or PAAD -Evaluate the performance of CLDN18.2 IHC assay in patients with STAD or PAAD -Evaluate anti-CAR-CLDN18.2 T-cell therapy (CT041) drug antibodies in patients with STAD or PAAD Cohort B Primary: -Determine the efficacy of CAR-CLDN18.2 T-cell therapy (CT041), in terms of ORR in patients with PAAD Secondary -Evaluate the safety and tolerability of CAR-CLDN18.2 T-cell therapy (CT041) in patients with PAAD -Evaluate additional clinical efficacy outcomes with CAR-CLDN18.2 T-cell therapy (CT041) in patients with PAAD Exploratory -Evaluate PK and biodistribution of CAR-CLDN18.2 T-cell therapy (CT041) in patients with PAAD -Evaluate the performance of CLDN18.2 IHC assay in patients with PAAD -Evaluate anti-CAR-CLDN18.2 T-cell therapy (CT041) drug antibodies in patients with PAAD

• Treatments

  Therapies:

  Cell Therapy

  Medications:

  CT041 (); Nab-paclitaxel (Abraxane); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

• Inclusion Criteria

  • Voluntarily signed the ICF
  • Age >18 and > Cohort A and B: Patients with STAD, PAAD or BTC
  • Cohort C: Patients with STAD
  • Must have CLDN18.2-positive tumor expression from a tumor sample collected > Life expectancy > 4 months
  • Must have prior lines of therapy defined by protocol
  • At least 1 measurable lesion per RECIST 1.1
  • ECOG performance status of 0 or 1
  • Sufficient venous access for leukapheresis collection and no other contraindications to leukapheresis
  • Patients should have reasonable CBC counts, renal and hepatic functions
  • Women of childbearing age must undergo a serum pregnancy test with negative results before screening and infusion and be willing to use effective and reliable method of contraception for at least 12 months after T-cell infusion.
  • Men must be willing to use effective and reliable method of contraception for at least 12 months after T-cell infusion
  • Sufficient nutritional status: Must must weigh >/= 38kg and females must weight >/= 34 kg. Patients must have > Additional criteria will apply

• Exclusion Criteria

  • Pregnant or lactating women
  • HIV, active hepatitis C virus (HCV), active hepatitis B virus (HBV) or active syphilis infection. History of treated hepatitis B or C is permitted if the viral load is undetectable per qPCR and/or nucleic acid testing.
  • Any uncontrolled active infection
  • AEs from previous treatment that have not recovered
  • Patients who have clinically significant thyroid dysfunction
  • Patients allergic to any drugs of the preconditioning regimen, tocilizumab, dimethyl sulfoxide (DMSO), or CT041 CAR-CLDN18.2 T-cell
  • Patients who have received prior cellular therapy such as (CAR T, TCR, tumor-infiltrating lymphocytes) or organ transplantation; Untreated central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression
  • Patients with heavy tumor burden such as significant lung disease
  • Unstable/active ulcer or digestive tract bleeding or recent digestive surgery that may have increased risk of bleeding
  • Patients who have a history of esophageal or gastric resection with increased risk of bleeding or perforation
  • Patients requiring anticoagulant therapy such as warfarin or heparin
  • Patients requiring long-term antiplatelet therapy
  • Use of prednisone or other equivalent within 14 days before leukapheresis or preconditioning
  • Anticancer treatment within approximately 2 weeks prior to leukapheresis or approximately 3 weeks before preconditioning
  • Major surgery less than 1 week prior to leukapheresis or 3 weeks prior to preconditioning
  • Patients have clinical significant cardiac conditions that researchers believe that participating in this clinical trial may endanger the health of the patients
  • Patients have clinical significant pulmonary conditions
  • Patients known to have active autoimmune diseases
  • Patients with second malignancies in addition to STAD or PAAD
  • Patients have significant neurologic disorders
  • Patients are unable or unwilling to comply with the requirements of clinical trial.
  • Additional criteria will apply

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.